Shuttle Pharmaceuticals
SHPH
8 hedge funds and large institutions have $107K invested in Shuttle Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
14% more funds holding
Funds holding: 7 → 8 (+1)
0.26% more ownership
Funds ownership: 0.73% → 0.99% (+0.26%)
49% less capital invested
Capital invested by funds: $210K → $107K (-$102K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$43.1K |
| 2 |
VF
Virtu Financial
New York
|
+$16.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.19K |
| 4 |
KFA
Kelleher Financial Advisors
New York
|
+$813 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$8.51K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$22 |
| 3 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$4 |
| 4 |
Citigroup
New York
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IC
1
Ikarian Capital
Dallas,
Texas
| $46.8K | – | – | – |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $31.4K | +$43.1K | +3,178 | +220% |
|
|
BFM
3
Boothbay Fund Management
New York
| $13.8K | – | – | – |
|
|
VF
4
Virtu Financial
New York
| $8K | +$16.8K | +1,238 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $3.85K | -$8.51K | -628 | -53% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $3.15K | +$5.19K | +383 | +473% |
|
|
KFA
7
Kelleher Financial Advisors
New York
| $407 | +$813 | +60 | New |
|
8
Morgan Stanley
New York
| $18 | – | – | – |
|
|
9
Bank of America
Charlotte,
North Carolina
| – | -$22 | -1 | Closed |
|
|
10
Citigroup
New York
| – | -$2 | – | – |
|
|
FDCDDQ
11
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$4 | – | – |
|
SHPH Hedge Fund Activity: Q1 2026 in Review
8 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Shuttle Pharmaceuticals (SHPH) for Q1 2026, worth a combined $107K — down 49% from $210K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new SHPH positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $43.1K. The largest seller was UBS Group, cutting an estimated $8.51K.
- 8 institutional investors held Shuttle Pharmaceuticals (SHPH) as of Q1 2026, up from 7 in Q4 2025.
- Funds reported $107K of Shuttle Pharmaceuticals stock for Q1 2026, down 49% quarter-over-quarter.
- 2 funds opened new Shuttle Pharmaceuticals positions in Q1 2026 and 1 closed out, a net change of +1 holder.
- The largest Shuttle Pharmaceuticals buyer in Q1 2026 was Geode Capital Management, an estimated $43.1K added.
- The largest Shuttle Pharmaceuticals seller in Q1 2026 was UBS Group, an estimated $8.51K sold.
Based on aggregated 13F filings for Q1 2026.